MAXCYTE, INC. (MXCT) [Rocket]

In millions, except per share items	Dec-31-22	Dec-31-21	Dec-31-20	Dec-31-19
	10-K	10-K	10-K	10-K
Revenues	28.7	21.6	15.5	13.3
Revenue growth	33.3%	39.6%	16.6%
Cost of goods sold	5.1	3.6	2.8	2.5
Gross profit	23.7	17.9	12.7	10.8
Gross margin	82.3%	83.1%	82.1%	81.1%
Selling, general and administrative [+]	44.5	31.7	15.7	13.4
Sales and marketing	18.7	13.0	8.3	7.9
General and administrative	25.8	18.7	7.4	5.6
Research and development	19.5	15.4	17.7	17.6
Other operating expenses	-15.8	-12.8	-11.0	-8.4
EBITDA [+]	-24.4	-16.2	-9.7	-11.8
EBITDA growth	50.2%	66.9%	-17.6%
EBITDA margin	-84.9%	-75.3%	-63.0%	-89.1%
Depreciation and amortization	2.7	1.4	1.0	0.6
EBIT [+]	-27.1	-17.7	-10.8	-12.4
EBIT growth	53.3%	63.9%	-13.2%
EBIT margin	-94.2%	-81.9%	-69.8%	-93.7%
Non-recurring items [+]	0.3	0.5	0.3
Asset impairment	0.3	0.5	0.3
Interest income, net [+]	3.9	0.2	0.1	0.2
Interest expense		0.0	0.0	0.1
Interest income	3.9	0.2	0.1	0.2
Other income (expense), net	-0.1	-1.0	-0.8	-0.6
Pre-tax income	-23.6	-19.1	-11.8	-12.9
Income taxes	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%
Net income	-23.6	-19.1	-11.8	-12.9
Net margin	-82.0%	-88.5%	-76.5%	-97.3%

Basic EPS [+]	($0.23)	($0.21)	($0.17)	($0.23)
Growth	10.1%	23.8%	-25.6%
Diluted EPS [+]	($0.23)	($0.21)	($0.17)	($0.23)
Growth	10.1%	23.8%	-25.6%

Shares outstanding (basic) [+]	101.7	90.6	69.5	56.4
Growth	12.2%	30.5%	23.2%
Shares outstanding (diluted) [+]	101.7	90.6	69.5	56.4
Growth	12.2%	30.5%	23.2%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.